-
Je něco špatně v tomto záznamu ?
Fibroblast Growth Factor 20 Attenuates Colitis by Restoring Impaired Intestinal Epithelial Barrier Integrity and Modulating Macrophage Polarization via S100A9 in an NF-κB-Dependent Manner
D. Zhen, S. Wang, Z. Liu, Y. Xi, H. Du, N. Wang, X. Gao, Z. Lin, F. Wu
Jazyk angličtina
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2015
PubMed Central
od 2015
Open Access Digital Library
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2015
- MeSH
- fibroblastové růstové faktory * metabolismus genetika farmakologie MeSH
- kalgranulin B * metabolismus genetika MeSH
- kolitida * chemicky indukované MeSH
- lidé MeSH
- makrofágy * imunologie metabolismus účinky léků MeSH
- modely nemocí na zvířatech MeSH
- myši inbrední C57BL MeSH
- myši knockoutované MeSH
- myši MeSH
- NF-kappa B * metabolismus MeSH
- signální transdukce MeSH
- síran dextranu toxicita MeSH
- střevní sliznice * patologie metabolismus imunologie účinky léků MeSH
- ulcerózní kolitida * patologie chemicky indukované imunologie metabolismus farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND & AIMS: Exogenous recombinant fibroblast growth factor 20 (FGF20) protein has been proved to treat ulcerative colitis; however, its mechanism of action remains unclear. This study aimed to explore the role and mechanism of action of FGF20 in ulcerative colitis. METHODS: Data from patients with ulcerative colitis were analyzed using the Gene Expression Omnibus dataset. A murine colitis model was established by administering 2% dextran sodium sulfate. FGF20 knockout mice and Adenoassociated viruses (AAV)-FGF20-treated mice were used to elucidate the specific mechanisms. Proteomic analysis was conducted to identify differentially expressed genes. RESULTS: FGF20 levels were significantly elevated in the colonic tissues of subjects and mice with colitis. FGF20 deficiency exacerbated dextran sodium sulfate-induced colitis; in contrast, FGF20 replenishment alleviated colitis through 2 principal mechanisms: restoration of impaired intestinal epithelial barrier integrity, and inhibition of M1 macrophage polarization. Notably, S100A9 was identified as a pivotal downstream target of FGF20, which was further demonstrated by pharmacologic inhibition and overexpression experiments of S100A9 using paquinimod (a specific inhibitor of S100A9) and AAV-S100A9 in FGF20 knockout and AAV-FGF20 mice with colitis, respectively. Additionally, the nuclear factor-κB pathway was found to be involved in the process by which FGF20 regulates S100A9 to counteract colitis. CONCLUSIONS: These results suggest that FGF20 acts as a negative regulator of S100A9 and nuclear factor-κB, thereby inhibiting M1 macrophage polarization and restoring intestinal epithelial barrier integrity in mice with dextran sodium sulfate-induced colitis. FGF20 may serve as a potential therapeutic target for the treatment of ulcerative colitis.
School of Pharmaceutical Sciences Wenzhou Medical University Wenzhou China
The 1st Affiliated Hospital of Wenzhou Medical University Wenzhou China
The Affiliated Songshan Lake Center Hospital Guangdong Medical University Dongguan China
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25016423
- 003
- CZ-PrNML
- 005
- 20250731092905.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jcmgh.2025.101486 $2 doi
- 035 __
- $a (PubMed)40024533
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a x
- 100 1_
- $a Zhen, Dong $u The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- 245 10
- $a Fibroblast Growth Factor 20 Attenuates Colitis by Restoring Impaired Intestinal Epithelial Barrier Integrity and Modulating Macrophage Polarization via S100A9 in an NF-κB-Dependent Manner / $c D. Zhen, S. Wang, Z. Liu, Y. Xi, H. Du, N. Wang, X. Gao, Z. Lin, F. Wu
- 520 9_
- $a BACKGROUND & AIMS: Exogenous recombinant fibroblast growth factor 20 (FGF20) protein has been proved to treat ulcerative colitis; however, its mechanism of action remains unclear. This study aimed to explore the role and mechanism of action of FGF20 in ulcerative colitis. METHODS: Data from patients with ulcerative colitis were analyzed using the Gene Expression Omnibus dataset. A murine colitis model was established by administering 2% dextran sodium sulfate. FGF20 knockout mice and Adenoassociated viruses (AAV)-FGF20-treated mice were used to elucidate the specific mechanisms. Proteomic analysis was conducted to identify differentially expressed genes. RESULTS: FGF20 levels were significantly elevated in the colonic tissues of subjects and mice with colitis. FGF20 deficiency exacerbated dextran sodium sulfate-induced colitis; in contrast, FGF20 replenishment alleviated colitis through 2 principal mechanisms: restoration of impaired intestinal epithelial barrier integrity, and inhibition of M1 macrophage polarization. Notably, S100A9 was identified as a pivotal downstream target of FGF20, which was further demonstrated by pharmacologic inhibition and overexpression experiments of S100A9 using paquinimod (a specific inhibitor of S100A9) and AAV-S100A9 in FGF20 knockout and AAV-FGF20 mice with colitis, respectively. Additionally, the nuclear factor-κB pathway was found to be involved in the process by which FGF20 regulates S100A9 to counteract colitis. CONCLUSIONS: These results suggest that FGF20 acts as a negative regulator of S100A9 and nuclear factor-κB, thereby inhibiting M1 macrophage polarization and restoring intestinal epithelial barrier integrity in mice with dextran sodium sulfate-induced colitis. FGF20 may serve as a potential therapeutic target for the treatment of ulcerative colitis.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a NF-kappa B $x metabolismus $7 D016328
- 650 12
- $a střevní sliznice $x patologie $x metabolismus $x imunologie $x účinky léků $7 D007413
- 650 12
- $a makrofágy $x imunologie $x metabolismus $x účinky léků $7 D008264
- 650 _2
- $a síran dextranu $x toxicita $7 D016264
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a myši knockoutované $7 D018345
- 650 12
- $a kalgranulin B $x metabolismus $x genetika $7 D040502
- 650 12
- $a ulcerózní kolitida $x patologie $x chemicky indukované $x imunologie $x metabolismus $x farmakoterapie $7 D003093
- 650 12
- $a fibroblastové růstové faktory $x metabolismus $x genetika $x farmakologie $7 D005346
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a signální transdukce $7 D015398
- 650 12
- $a kolitida $x chemicky indukované $7 D003092
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Wang, Songxue $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- 700 1_
- $a Liu, Zhen $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- 700 1_
- $a Xi, Yiyuan $u The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- 700 1_
- $a Du, Hanlin $u The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- 700 1_
- $a Wang, Ningrui $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- 700 1_
- $a Gao, Xiaotang $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
- 700 1_
- $a Lin, Zhuofeng $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China; The Affiliated Songshan Lake Center Hospital, Guangdong Medical University, Dongguan, China. Electronic address: zlin@gdmu.edu.cn
- 700 1_
- $a Wu, Fan $u The Affiliated Songshan Lake Center Hospital, Guangdong Medical University, Dongguan, China. Electronic address: zflwf@126.com
- 773 0_
- $w MED00211331 $t Cellular and molecular gastroenterology and hepatology $x 2352-345X $g Roč. 19, č. 6 (2025), s. 101486
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40024533 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731092859 $b ABA008
- 999 __
- $a ok $b bmc $g 2366930 $s 1253548
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 19 $c 6 $d 101486 $e 20250228 $i 2352-345X $m Cellular and molecular gastroenterology and hepatology $n Cell Mol Gastroenterol Hepatol $x MED00211331
- LZP __
- $a Pubmed-20250708